CN1444926A - 生物粘着性药物释放系统 - Google Patents

生物粘着性药物释放系统 Download PDF

Info

Publication number
CN1444926A
CN1444926A CN02127087A CN02127087A CN1444926A CN 1444926 A CN1444926 A CN 1444926A CN 02127087 A CN02127087 A CN 02127087A CN 02127087 A CN02127087 A CN 02127087A CN 1444926 A CN1444926 A CN 1444926A
Authority
CN
China
Prior art keywords
composition
therapeutically active
phase
acidic buffer
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN02127087A
Other languages
English (en)
Chinese (zh)
Inventor
米切尔·I·基施纳
R·索尔·莱文森
托马斯·C·赖利
马克·S·赫尔梅林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kv Pharmaceutical Co
Original Assignee
Kv Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22282669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1444926(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kv Pharmaceutical Co filed Critical Kv Pharmaceutical Co
Publication of CN1444926A publication Critical patent/CN1444926A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN02127087A 2002-03-20 2002-07-29 生物粘着性药物释放系统 Pending CN1444926A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/101014 2002-03-20
US10/101,014 US6899890B2 (en) 2002-03-20 2002-03-20 Bioadhesive drug delivery system

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNA2007101048008A Division CN101045034A (zh) 2002-03-20 2002-07-29 生物粘着性药物释放系统
CN2010105156408A Division CN102048689A (zh) 2002-03-20 2002-07-29 生物粘着性药物释放系统

Publications (1)

Publication Number Publication Date
CN1444926A true CN1444926A (zh) 2003-10-01

Family

ID=22282669

Family Applications (3)

Application Number Title Priority Date Filing Date
CN02127087A Pending CN1444926A (zh) 2002-03-20 2002-07-29 生物粘着性药物释放系统
CNA2007101048008A Pending CN101045034A (zh) 2002-03-20 2002-07-29 生物粘着性药物释放系统
CN2010105156408A Pending CN102048689A (zh) 2002-03-20 2002-07-29 生物粘着性药物释放系统

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA2007101048008A Pending CN101045034A (zh) 2002-03-20 2002-07-29 生物粘着性药物释放系统
CN2010105156408A Pending CN102048689A (zh) 2002-03-20 2002-07-29 生物粘着性药物释放系统

Country Status (17)

Country Link
US (1) US6899890B2 (cg-RX-API-DMAC7.html)
EP (1) EP1494630A4 (cg-RX-API-DMAC7.html)
JP (1) JP4462818B2 (cg-RX-API-DMAC7.html)
KR (2) KR20030076159A (cg-RX-API-DMAC7.html)
CN (3) CN1444926A (cg-RX-API-DMAC7.html)
AR (1) AR039037A1 (cg-RX-API-DMAC7.html)
AU (2) AU2002300175B2 (cg-RX-API-DMAC7.html)
BR (1) BR0202767A (cg-RX-API-DMAC7.html)
CA (1) CA2392473C (cg-RX-API-DMAC7.html)
FR (1) FR2837389A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0203102A3 (cg-RX-API-DMAC7.html)
IT (1) ITMI20021660A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA02006943A (cg-RX-API-DMAC7.html)
PT (1) PT102854B (cg-RX-API-DMAC7.html)
RU (1) RU2320322C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003079981A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200407535B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799198A (zh) * 2016-11-30 2020-02-14 普罗生物瑞士股份公司 用于稳定阴道液的酸度和氧化还原状态的基于合适的生化组合物的泌尿生殖器医疗设备制剂

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189552A1 (en) * 2000-12-12 2006-08-24 Mohan Vishnupad Dispenser for dispensing three or more actives
US7060732B2 (en) * 2000-12-12 2006-06-13 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
US20050037033A1 (en) * 2003-05-23 2005-02-17 Program For Appropriate Technology In Health Microbicidal compositions and methods and use
ITTO20030404A1 (it) * 2003-05-30 2004-11-30 Rottapharm S R L Composizione per il ripristino dell'ecosistema vaginale
GB0315671D0 (en) * 2003-07-04 2003-08-13 Chelsea And Westminster Nhs Tr Improvements in or relating to organic compounds
US20060140990A1 (en) 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
SG146638A1 (en) 2003-09-19 2008-10-30 Drugtech Corp Pharmaceutical delivery system
CA2547990C (en) * 2003-12-08 2011-08-02 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
US8057433B2 (en) 2004-07-08 2011-11-15 Drugtech Corporation Delivery system
UA93354C2 (ru) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US7619008B2 (en) * 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
US20060217443A1 (en) * 2005-03-28 2006-09-28 Kimberly-Clark Worldwide, Inc. Method for preventing and/or treating vaginal and vulval infections
CN101175503B (zh) * 2005-04-27 2012-12-12 深圳福诺生物技术有限公司 一种调节并保持阴道菌群和阴道酸度正常的组合物与方法
WO2006121429A1 (en) * 2005-05-06 2006-11-16 Imaginative Research Associates, Inc. Clindamycin compositions and delivery system therefor
CA2605341A1 (en) * 2005-05-09 2006-11-16 Drugtech Corporation Modified-release pharmaceutical compositions
US7786176B2 (en) * 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
DK1933810T3 (da) * 2005-08-11 2013-01-28 Childrens Medical Center Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde
PE20070329A1 (es) * 2005-08-12 2007-03-29 Drugtech Corp Composiciones con estrogenos y metodos terapeuticos para su uso
BRPI0620907A2 (pt) * 2006-01-05 2011-11-29 Drugtech Corp composição farmacêutica, sistema de distribuição de droga vaginal e uso da composição farmacêutica
AU2006332518A1 (en) * 2006-01-05 2007-07-12 Drugtech Corporation Composition and method of use thereof
JP2009526064A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション 薬学的調合物
EP1872775A1 (en) * 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
US20080003262A1 (en) * 2006-06-30 2008-01-03 Drugtech Corporation Compositions and therapeutic methods of use
US20080085877A1 (en) * 2006-08-10 2008-04-10 Drugtech Corporation Therapeutic methods of using estrogen compositions
US20080268022A1 (en) * 2007-02-23 2008-10-30 Mccabe R Tyler Mehtods for treating and preventing ailments caused by human papillomavirus
US20080287408A1 (en) * 2007-05-14 2008-11-20 Drugtech Corporation Endometriosis treatment
EP1994938A1 (en) * 2007-05-21 2008-11-26 Combinature Biopharm AG New lipoglycodepsipeptide compositions
NZ585449A (en) 2007-12-11 2012-07-27 Massachusetts Inst Technology Implantable drug delivery device and methods for treatment of the bladder and other body vestcles or lumens
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
WO2010019507A2 (en) * 2008-08-09 2010-02-18 Massachusetts Institute Of Technology Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues
WO2010097344A1 (en) * 2009-02-26 2010-09-02 Basf Se Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin
BRPI1014771B1 (pt) 2009-06-26 2020-04-14 Liris Biomedical Inc dispositivo de dispensação de droga
US20110008469A1 (en) * 2009-07-09 2011-01-13 Florida Gulf Coast University Antimicrobial composition and methods and apparatus for use thereof
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
RU2479305C2 (ru) * 2010-12-06 2013-04-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения инфекционных воспалительных заболеваний в гинекологии и способ ее получения
CA2823783C (en) 2011-01-10 2023-03-21 Taris Biomedical, Inc. Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
CN103379902B (zh) 2011-02-04 2015-11-25 塔里斯生物医药公司 用于低溶解度药物的控制释放的可植入装置
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
CA2829181C (en) 2011-04-04 2016-01-05 Environ Skin Care (Pty) Ltd The treatment of viral infections
AU2012250862B2 (en) 2011-05-02 2015-07-09 Adare Pharmaceuticals, Inc. Rapid dissolve tablet compositions for vaginal administration
EP2757904B1 (en) * 2011-09-19 2017-01-11 OmniActive Health Technologies Limited An efficient process for the preparation of lycopene containing oleoresin and lycopene crystals for human consumption
US9180094B2 (en) 2011-10-12 2015-11-10 The Texas A&M University System High porosity materials, scaffolds, and method of making
KR101811917B1 (ko) * 2012-01-19 2017-12-22 더 존스 홉킨스 유니버시티 점액 침투 강화를 나타내는 나노 입자 제형
WO2014018075A1 (en) 2012-07-23 2014-01-30 Crayola, Llc Dissolvable films and methods of using the same
RU2538703C2 (ru) * 2013-03-12 2015-01-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения вагинального кандидоза и способ ее получения
SG11201507294WA (en) 2013-03-15 2015-10-29 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
JP6341200B2 (ja) * 2013-05-30 2018-06-13 大正製薬株式会社 坐剤
HUE051336T2 (hu) 2013-08-19 2021-03-01 Taris Biomedical Llc Többadagos gyógyszeradagoló eszköz
US10363215B2 (en) 2013-11-08 2019-07-30 The Texas A&M University System Porous microparticles with high loading efficiencies
US20150238549A1 (en) * 2014-02-27 2015-08-27 Mak Wood, Inc. Probiotic dosage units
EP3113824B1 (en) 2014-03-03 2021-04-14 Cook Medical Technologies LLC Mechanical dilator
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
US10894150B2 (en) 2015-04-23 2021-01-19 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
CN107847434A (zh) 2015-05-29 2018-03-27 Eve制药有限公司 Ph依赖型阴道组合物和治疗阴道病症的方法
RU2709464C2 (ru) 2015-09-29 2019-12-18 Кимберли-Кларк Ворлдвайд, Инк. Синергическая композиция для сохранения здорового баланса микрофлоры
KR101880179B1 (ko) * 2016-11-03 2018-07-20 한국생명공학연구원 미카펀진(micafungin) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 항바이러스용 약학적 조성물
WO2018160158A1 (en) 2017-02-28 2018-09-07 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
WO2020132098A1 (en) * 2018-12-19 2020-06-25 Healthy Cow Corporation Ready-to-use probiotic compositions and uses thereof
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
US11529346B2 (en) * 2020-06-18 2022-12-20 National Medical Supply, LLC Vaginal gel

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988508A (en) * 1973-03-08 1976-10-26 Petrolite Corporation High internal phase ratio emulsion polymers
DE3321043A1 (de) * 1983-06-10 1984-12-13 Bayer Ag, 5090 Leverkusen Antimykotische mittel fuer einmalige gynaekologische behandlung
US4551148A (en) * 1982-09-07 1985-11-05 Kv Pharmaceutical Company Vaginal delivery systems and their methods of preparation and use
US5266329A (en) * 1985-10-31 1993-11-30 Kv Pharmaceutical Company Vaginal delivery system
US5536743A (en) * 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US4895452A (en) * 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5055303A (en) * 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
CA1337279C (en) 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5298246A (en) * 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
KR100259989B1 (ko) * 1991-10-01 2000-08-01 모리다 가쓰라 서방성 마이크로캡슐 제제 및 그의 제조법
US5189070A (en) * 1992-05-29 1993-02-23 Shell Oil Company Process for preparing low density porous crosslinked polymeric materials
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5470885A (en) * 1993-09-29 1995-11-28 The Research Foundation Of The State University Of New York Fluorocarbons as anti-inflammatory agents
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5980936A (en) * 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
WO1999021562A1 (en) * 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799198A (zh) * 2016-11-30 2020-02-14 普罗生物瑞士股份公司 用于稳定阴道液的酸度和氧化还原状态的基于合适的生化组合物的泌尿生殖器医疗设备制剂

Also Published As

Publication number Publication date
PT102854B (pt) 2004-02-27
RU2004130870A (ru) 2005-06-10
AU2002300175A1 (en) 2003-10-09
ITMI20021660A1 (it) 2004-01-26
FR2837389A1 (fr) 2003-09-26
WO2003079981A2 (en) 2003-10-02
KR20080098576A (ko) 2008-11-11
AU2003218233A1 (en) 2003-10-08
HUP0203102A3 (en) 2004-06-28
MXPA02006943A (es) 2004-12-13
CA2392473A1 (en) 2003-09-20
EP1494630A2 (en) 2005-01-12
KR20030076159A (ko) 2003-09-26
CN102048689A (zh) 2011-05-11
PT102854A (pt) 2003-09-30
US20030180366A1 (en) 2003-09-25
HUP0203102A2 (hu) 2004-05-28
US6899890B2 (en) 2005-05-31
AU2003218233A8 (en) 2003-10-08
JP4462818B2 (ja) 2010-05-12
RU2320322C2 (ru) 2008-03-27
EP1494630A4 (en) 2007-03-14
CN101045034A (zh) 2007-10-03
ZA200407535B (en) 2006-06-28
AR039037A1 (es) 2005-02-02
CA2392473C (en) 2007-09-18
AU2002300175B2 (en) 2004-04-22
JP2003286193A (ja) 2003-10-07
BR0202767A (pt) 2004-05-25
WO2003079981A3 (en) 2003-11-06
HU0203102D0 (cg-RX-API-DMAC7.html) 2002-11-28

Similar Documents

Publication Publication Date Title
CN1444926A (zh) 生物粘着性药物释放系统
US9789057B2 (en) Pharmaceutical delivery system
JP2999820B2 (ja) 緩衝メトロニダゾール組成物による膣感染症の改良された膣内治療
CN101374502A (zh) 局部应用的药剂
HK1045934B (zh) 缓释型生物粘附性阴道凝胶剂型
MX2008001687A (es) Composiciones de estrogenos y metodos terapeuticos de uso.
Gupta et al. Exploring novel approaches to vaginal drug delivery
CN102000339A (zh) 缓释释药的药物载体
CN1361694A (zh) 粘膜吸收甘草甜素制剂
KR20080083190A (ko) 외음질 표면에 생체접착을 위한 약물 전달 시스템
HK1055902A (en) Bioadhesive drug delivery system
JP2008504272A (ja) 薬物送達のための医薬組成物及びそれを使用する症状の治療又は予防法
WO2016204598A1 (es) Composición farmaceutica de uso veterinario basada en una suspensión de progesterona en un sistema polimérico, que tiene propiedades de gelificacion in situ
MXPA06003131A (en) Pharmaceutical delivery system

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1055902

Country of ref document: HK